What is Incyte's olumiant royalty revenues — total revenues?

Incyte (INCY) reported olumiant royalty revenues — total revenues of $36.41M in Q1 2026.

How has Incyte's olumiant royalty revenues — total revenues changed year-over-year?

Incyte's olumiant royalty revenues — total revenues increased by 18.2% year-over-year, from $30.80M to $36.41M.

What does olumiant royalty revenues — total revenues mean?

The total royalty income earned by the company from a third-party partner's sales of a licensed pharmaceutical product.

OLUMIANT Royalty Revenues — Total revenues

Incyte OLUMIANT Royalty Revenues — Total revenues decreased by 1.9% to $36.41M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.2%, from $30.80M to $36.41M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2024

Last reportedQ1 2026Apr 28, 2026

Rolls up toTotal Revenue

How to read this metric

An increase indicates strong commercial adoption and sales growth of the licensed drug by the partner, while a decrease suggests declining market demand or increased competition.

Detailed definition

This metric represents the total gross royalty income recognized by the company from the licensing of a pharmaceutical p...

Peer comparison

Comparable to royalty revenue streams reported by other biotechnology firms that license out drug candidates to larger pharmaceutical partners.

Metric ID: incy_segment_olumiant_royalty_revenues_total_revenues

Historical Data

7 periods

	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q1 '26
Value	$30.59M	$31.70M	$34.80M	$30.80M	$33.48M	$37.11M	$36.41M
QoQ Change	—	+3.6%	+9.8%	-11.5%	+8.7%	+10.8%	-1.9%
YoY Change	—	—	—	+0.7%	+5.6%	+6.7%	+18.2%

Range$30.59M – $37.11M

CAGR+12.3%

Avg YoY Growth+7.8%

Median YoY Growth+6.1%

Similar Metrics at Other Companies

BiogenBIIB View metric

Royalty PharmaRPRX View metric

ModernaMRNA View metric

BiogenBIIB View metric

InsmedINSM View metric

Frequently Asked Questions

What is Incyte's olumiant royalty revenues — total revenues?: Incyte (INCY) reported olumiant royalty revenues — total revenues of $36.41M in Q1 2026.
How has Incyte's olumiant royalty revenues — total revenues changed year-over-year?: Incyte's olumiant royalty revenues — total revenues increased by 18.2% year-over-year, from $30.80M to $36.41M.
What does olumiant royalty revenues — total revenues mean?: The total royalty income earned by the company from a third-party partner's sales of a licensed pharmaceutical product.